Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabCute: Extended Rituximab Maintenance in Indolent NHL
NCT01461928Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2011
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in Indolent Non-Hodgkin Lymphoma (INHL) comparing Maintenance II Rituximab with Maintenance II Observation (2 arms). Primary endpoint: Progression-free Survival up to 24 months. Started Dec 2011; status: completed.
02
Drugs
rituximab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01461928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461928.